DanielaAnnenelieBotaMDPhD
Neurology • Costa Mesa, CANeurooncology
Vice Dean, Clinical Research Director, Alpha Clinic Professor, Neurology, University of California, Irvine School of Medicine
Dr. Bota is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1640 Newport Blvd
Ste 400
Costa Mesa, CA 92627Phone+1 949-999-2400Fax+1 949-999-2405
Summary
- Dr. Daniela Bota is a Neurological Oncologist in Irvine, CA and is affiliated with UCI Medical Center. She received her medical degree from Carol Davila University of Medicine and Pharmacy and has been in practice 20 years. She specializes in neurooncology and is experienced in neuro-oncology, gliomas, primary brain tumors, and antineoplastic agents.
Education & Training
Duke University HospitalFellowship, Neurologic Oncology, 2006 - 2007
University of Kansas School of MedicineResidency, Neurology, 2003 - 2006
Carol Davila University of Medicine and PharmacyClass of 1997
Certifications & Licensure
CA State Medical License 2007 - 2027
NC State Medical License 2006 - 2008
American Board of Psychiatry and Neurology Neurology
AOA Board of Neurology and Psychiatry Neurology
Clinical Trials
- Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
- Neurological Surgery & Affiliated Services De-Identified Clinical Outcomes Database Start of enrollment: 2005 Aug 04
- Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer Start of enrollment: 2011 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Dual targeting of the mitochondrial Lon peptidase 1 and the chymotrypsin-like proteasome activity as a potential therapeutic strategy in malignant astrocytoma models.Christopher Douglas, Shashi Jain, Naomi Lomeli, Javier Lepe, Kaijun Di
Pharmacological Research. 2025-03-13 - 2 citationsReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.Christopher L Moertel, Angela C Hirbe, Hans H Shuhaiber, Kevin Bielamowicz, Alpa Sidhu
Journal of Clinical Oncology. 2025-02-20 - Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.Mohamed A Gouda, Zihan Wei, Jordi Rodon, Michael A Davies, Filip Janku
JCO Precision Oncology. 2025-02-01
Press Mentions
Honoring Dr. John Zaia: A Legacy of Science, Leadership, and KindnessFebruary 27th, 2025- Cell and Gene Therapies Symposium Open to PublicOctober 24th, 2024
- With Award of $8 Million, UC Irvine and Regional Partners Will Expand Stem Cell TreatmentsOctober 31st, 2022
- Join now to see all
Grant Support
- Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous systemUNIVERSITY OF CALIFORNIA-IRVINE2021–2026
- Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous systemUNIVERSITY OF CALIFORNIA-IRVINE2021–2026
- Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous systemUNIVERSITY OF CALIFORNIA-IRVINE2021–2026
- Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous systemUNIVERSITY OF CALIFORNIA-IRVINE2021–2026
- Targeting of Mitochondrial Lon Protease as a Novel Therapy for GlioblastomaUNIVERSITY OF CALIFORNIA-IRVINE2020–2025
- Targeting of Mitochondrial Lon Protease as a Novel Therapy for GlioblastomaUNIVERSITY OF CALIFORNIA-IRVINE2020–2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
